Hair Relaxer Cancer Litigation Trial Will Begin in 2027
The first bellwether trial in the chemical hair straightener litigation will address health claims on September 9, 2027.
Updated on Sept. 30, 2026 in Cancer
Live Poll
Should large corporations be held liable for health risks linked to their personal care products?
A federal court has officially scheduled the first bellwether trial in the multidistrict litigation linking chemical hair relaxers to uterine, endometrial, and ovarian cancers for September 9, 2027. This proceeding will be the first to test these health claims in a courtroom setting.
Why it matters
This trial is a critical step in determining how the legal system will evaluate the potential health risks associated with long-term use of certain chemical hair products. Understanding these findings can help patients monitor for specific cancer symptoms and have informed conversations with their healthcare providers.
The federal court selected 10 representative bellwether cases to proceed to trial from the broader multidistrict litigation. These initial cases will serve as test trials to provide data on how future claims may be handled, though final results for the litigation are not yet established.
The players
Mary M. Rowland
The federal judge overseeing the multidistrict litigation regarding chemical hair products.
L'Oreal USA Inc.
A global beauty company that manufactures various personal care products and is a primary defendant in the hair relaxer litigation.
The details
The multidistrict litigation centers on allegations that chemical hair straighteners and relaxers may contribute to the development of ovarian, endometrial, and uterine cancers. The court-selected bellwether cases aim to provide a representative look at the evidence, which legal experts use to gauge potential jury reactions and evidentiary strength for thousands of similar claims. These proceedings represent the first formal judicial testing of these medical links.
Timeline
April 2026: The judge selected 10 bellwether trial cases.
September 24, 2026: The court issued the official docket entry setting the trial date.
January 28, 2027: A series of case management conferences will begin.
September 9, 2027: The first bellwether trial will commence.
Health Landscape
This case follows a pattern set by the talcum powder multidistrict litigation, where early bellwether trials shaped subsequent settlement negotiations and risk assessments for manufacturers. These proceedings mark a major shift in how the medical and legal communities evaluate the safety of common hair care products.
If you are concerned about your personal history of hair product use, it is worth discussing your health and any symptoms of uterine, endometrial, or ovarian cancer with your primary care doctor or a gynecologist. Your physician can help you evaluate your specific risk profile based on current medical guidance.
The takeaway
The upcoming trial highlights the growing importance of tracking potential long-term health effects related to personal care products. Discuss any concerns about persistent gynecological symptoms or your chemical exposure history during your next routine wellness checkup.
What happens next
A series of case management conferences are scheduled to begin on January 28, 2027, ahead of the September 9, 2027 trial date.
Further reading
For broader information regarding potential environmental and chemical exposures linked to malignancy, visit our Cancer section.
Source note: This article includes information reported by Harrismartin.
Live Poll
Should large corporations be held liable for health risks linked to their personal care products?
